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abstract
PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab
maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in
patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival
(OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety.
METHODS Patients (. 18 years of age) with previously untreated high–tumor-burden follicular lymphoma were
nonrandomly assigned to receive one of three immunochemotherapy induction regimens. Responding patients
were randomly assigned (stratified by induction regimen, response to induction treatment, treatment center, and
geographic region) 1:1 to receive 2 years of rituximab maintenance (375 mg/m2, once every 8 weeks), starting
8 weeks after the last induction treatment, or observation (no additional treatment). All patients in the extended
follow-up provided their written informed consent (data cutoff: December 31, 2016).
RESULTS In total, 1,018 patients completed induction treatment and were randomly assigned to rituximab
maintenance (n = 505) or observation (n = 513). Consent for the extended follow-up was provided by 607
patients (59.6%) of 1,018 (rituximab maintenance, n = 309; observation, n = 298). After data cutoff, median
PFS was 10.5 years in the rituximab maintenance arm compared with 4.1 years in the observation arm (hazard
ratio, 0.61; 95% CI, 0.52 to 0.73; P , .001). No OS difference was seen in patients randomly assigned to
rituximab maintenance or observation (hazard ratio, 1.04; 95% CI, 0.77 to 1.40; P = .7948); 10-year OS
estimates were approximately 80% in both study arms. No new safety signals were observed.
CONCLUSION Rituximab maintenance after induction immunochemotherapy provides a significant long-term
PFS, but not OS, benefit over observation.
J Clin Oncol 37:2815-2824. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Follicular lymphoma (FL) is the second most common
lymphoma subtype in the United States and Western
Europe, accounting for approximately 25% of all non-
Hodgkin lymphoma cases and 70% of indolent
lymphomas.1-3 Although the prognosis of patients with
FL has significantly improved since the introduction of
rituximab to first-line (1L) and salvage therapies,4-10
advanced-stage FL is believed to remain incurable in
most patients because of inevitable relapses; however,
strides have been made to prolong the duration of re-
mission without exposure to additional cytotoxic treatment.
Previous studies have demonstrated a significant clin-
ical benefit for rituximab maintenance in patients with
relapsed disease after induction with chemotherapy
with or without rituximab9-11 or single-agent rituximab,12,13
and in patients undergoing autologous stem-cell trans-
plantation.14 Rituximab maintenance after chemo-
therapy15 or single-agent rituximab16 has also been
studied in patients with previously untreated FL, with
favorable results; however, neither of these induction
regimens is considered optimal for patients with
advanced-stage disease.
The pivotal PRIMA study (ClinicalTrials.gov identifier:
NCT00140582) was the first phase III trial, to our
knowledge, to evaluate the potential benefit of 2 years
of rituximabmaintenance in patients with high–tumor-
burden FL responding to 1L rituximab-containing
immunochemotherapy.17 After a median follow-
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prolonged progression-free survival (PFS) compared with
observation; risk of disease progression was reduced by
45% (hazard ratio [HR], 0.55; 95% CI, 0.44 to 0.68; P ,
.001), and 3-year PFS rates were 74.9% and 57.6%, re-
spectively. This PFS benefit was achieved regardless of the
induction regimen, response to induction treatment, or
patient age. Time to next antilymphoma treatment (TTNLT)
and time to next chemotherapy treatment (TTNCT) were
also significantly prolonged with rituximab maintenance,
but no overall survival (OS) benefit was seen. An updated
6-year follow-up of the PRIMA study confirmed these
results.18 Rituximab maintenance is now widely recom-
mended for patients with FL responding to 1L rituximab-
based immunochemotherapy.19 We present the final PFS
and OS results from the PRIMA study after 9 years of
follow-up and a final overview of safety.
METHODS
Study Design, Patients, and Treatments
PRIMA was an open-label, international, multicenter,
randomized phase III trial in patients with previously un-
treated, high–tumor-burden FL. The study comprised two
phases: induction and maintenance or observation (un-
dertaken between December 2004 and April 2007, in 223
centers in 25 countries). Patients eligible for induction
therapy were older than 18 years with untreated FL (histo-
logic grade 1, 2, or 3a), diagnosed by a lymph node biopsy
performed within 4 months of study registration. Inclusion
and exclusion criteria are described in full elsewhere.17
During the induction phase, patients received rituximab in
combination with cyclophosphamide, doxorubicin, vin-
cristine, and prednisone (CHOP; six cycles); cyclophos-
phamide, vincristine, and prednisone (CVP; eight cycles);
or fludarabine, cyclophosphamide, and mitoxantrone
(FCM; six cycles).17 Each center selected their preferred
regimen for all patients enrolled at that center. Rituximab
(375 mg/m2) was administered intravenously on day 1 of
each chemotherapy course. CHOP- and FCM-treated pa-
tients received two additional rituximab infusions to ensure
equivalent exposure during the induction phase.
Response was assessed 2 to 4 weeks after last induction
treatment. Patients achieving a complete response (CR),
an unconfirmed complete response (CRu), or a partial
response (PR) were eligible for the next study phase. Eli-
gible patients must have received at least four cycles of
rituximab plus CHOP , six cycles of rituximab plus CVP, or
four cycles of rituximab plus FCM. At least six infusions of
rituximab were required for each treatment regimen,
without a delay of more than 2 weeks between each cycle.
Responding patients were randomly assigned 1:1 to re-
ceive rituximab maintenance (375 mg/m2, once every
8 weeks), starting 8 weeks after last induction treatment,
or observation (no additional treatment). All randomly
assigned patients received rituximab maintenance or
underwent observation for 2 years or until disease pro-
gression, whichever occurred first. The random assignment
procedure has been reported previously.17 Patients who
completed this phase were initially followed for 3 years
(data cutoff: January 31, 2011, per initial protocol) or
5 years (data cutoff: January 31, 2013, per protocol
amendment). Patients in this extended follow-up study
consented in writing to approximately 2 more years of
follow-up (data cutoff: December 31, 2016).
PRIMA was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines. The study
protocol and amendments were approved by local and
national ethics committees, according to the laws of each
country. Patients provided written informed consent.
Assessments
Response was evaluated according to the 1999 Interna-
tional Working Group response criteria for non-Hodgkin
lymphoma.20 During the 2-year rituximab maintenance or
observation phase, patients were assessed by clinical ex-
amination every 8 weeks and had a computed tomogra-
phy scan every 6 months. If bone marrow involvement
was initially documented, a biopsy was required at the end-
of-treatment assessment to confirm CR. Patients completing
the rituximab maintenance or observation phase underwent
a final restaging assessment within 28 days of the last
rituximab dose (or within a corresponding timeframe for
those randomly assigned to observation). For patients with
no disease progression, follow-up assessments were
scheduled every 3 months for the first 2 years, then every
6 months for an additional 3 years, and then annually in
patients consenting to the extended follow-up. Patients
with disease progression were followed annually for the
initiation of new treatment and OS for 5 years, or until data
cutoff in patients consenting to the extended follow-up.
Efficacy and Safety Analyses
The primary end point was investigator-assessed PFS.
Secondary end points included TTNLT, TTNCT, OS, and
transformation rate at relapse. Safety outcome measures
included adverse events (AEs), serious AEs, grade 3 or
higher AEs, and deaths. Grading of AEs was according to
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0.
Statistical Analysis
PFS was defined as the time from random assignment to
progression, relapse, or death from any cause. Responding
patients and patients lost to follow-up were censored at
their last tumor assessment date. OS was determined from
the date of random assignment to the date of death re-
gardless of cause. Survival end points were estimated by
Kaplan-Meier methodology and compared using a two-
sided log-rank test stratified by induction regimen and
induction response. Histologic transformation rates at first
relapse were compared using a x2 test.
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RESULTS
Patients
Overall, 1,018 patients completed induction treatment and
were randomly assigned to rituximab maintenance (n = 505)
or observation (n = 513); these patients were the primary
population for efficacy analyses. Nine patients (rituximab
maintenance, n = 4; observation, n = 5) withdrew before the
first maintenance treatment cycle or observation visit and
were excluded from the safety analyses. Consent for the
extended follow-up was provided by 607 patients (59.6%) of
1,018 (rituximab maintenance, n = 309; observation, n =
298). An overview of the trial profile is provided in Figure 1.
Median duration of follow-up was 9.0 years (range, 0.0 to
11.5 years) from random assignment and was well balanced
between arms (rituximab maintenance, 9.1 years; obser-
vation, 9.0 years). Patient demographics and disease
characteristics at random assignment are listed in Table 1.
Patients not included in the extended follow-up exhibited
adverse prognostic factors more frequently than those in
the extended follow-up, mainly because of the automatic
exclusion of patients who died before the current analysis
[data not shown]).
Efficacy
Rituximab maintenance after rituximab-containing in-
duction immunochemotherapy continued to provide
a significant long-term PFS benefit compared with obser-
vation (Table 2; Fig 2A). At the final data cutoff, median PFS
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FIG 1. CONSORT diagram. Full details of the
trial profile before follow-up have been
published previously.17 CHOP, cyclophos-
phamide, doxorubicin, vincristine, and
prednisone; CVP, cyclophosphamide, vin-
cristine, and prednisone; FCM, fludarabine,
cyclophosphamide, and mitoxantrone; ITT,
intent-to-treat.
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maintenance versus 4.1 years in patients randomly
assigned to observation (HR, 0.61; 95% CI, 0.52 to 0.73;
P , .001). Ten-year PFS estimates were 51.1% in the
rituximab maintenance arm and 35.0% in the observation
arm. Evaluation of PFS in prespecified patient subgroups,
categorized by age, sex, FLIPI score, induction chemo-
therapy, and response to induction, showed a consistent
benefit of rituximab maintenance over observation (Fig 3).
Patients in CR, CRu, or PR at end of induction consistently
benefited from rituximab maintenance (Data Supplement).
PFS by FLIPI risk factor category in the two treatment arms
is shown in the Data Supplement.
Rituximab maintenance also provided a significant benefit
over observation in terms of time to next treatment; median
TTNLT was not reached in the rituximab maintenance arm
versus 6.1 years in the observation arm (HR, 0.66; 95% CI,
0.55 to 0.78; P , .001; Table 2; Fig 2B). At the final data
cutoff, 212 patients (42.0%) of 505 in the rituximab
maintenance arm and 284 patients (55.4%) of 513 in the
observation arm had either started a new antilymphoma
treatment or died before receiving it. Ten-year TTNLT es-
timates were 53.4% in the rituximab maintenance arm and
41.2% in the observation arm.
Median TTNCT was not reached in the rituximab
maintenance arm versus 9.3 years in the observation arm
(HR, 0.71; 95% CI, 0.59 to 0.86; P , .001; Table 2;
Fig 2C); at data cutoff, 188 patients (37.2%) of 505 in
the rituximab maintenance arm and 244 patients
TABLE 1. Baseline Patient Demographics and Disease Characteristics (MITT, extended follow-up population, and no extended follow-up population)
Characteristic













Age . 60 years 180 (35.1) 176 (34.9) 91 (30.5) 95 (30.7) 89 (41.4) 81 (41.3)
Median age, years (range) 55 (22-84) 57 (26-79) 54 (27-80) 57 (26-77) 57 (22-84) 58 (31-79)
Sex, male 263 (51.2) 270 (53.5) 147 (49.3) 173 (56.0) 116 (54.0) 97 (49.5)
Ann Arbor stage III or IV 459 (89.5) 459 (90.9) 266 (89.3) 279 (90.3) 193 (89.8) 180 (91.8)
ECOG PS $ 1 172 (33.5) 181 (35.8) 88 (29.5) 104 (33.7) 84 (39.1) 77 (39.3)
“B” symptoms present 156 (30.4) 160 (31.7) 76 (25.5) 88 (28.5) 80 (37.2) 72 (36.7)
Bone marrow involvement 285 (55.6) 275 (54.5) 163 (54.7) 168 (54.4) 122 (58.1)a 107 (54.9)b
Lactate dehydrogenase . ULN 164 (32.0)b 173 (34.3)c 83 (27.9)b 93 (30.2)b 81 (37.7) 80 (41.0)b
Hemoglobin , 120 g/L 96 (18.7) 100 (19.8) 45 (15.1) 46 (14.9) 51 (23.7) 54 (27.6)
b2-microglobulin $ 3 mg/L 132 (27.8)d 148 (31.6)e 69 (25.2)f 76 (26.1)g 63 (31.3)h 72 (40.7)i
FLIPI scorej
Low (0-1 risk factors) 110 (21.4) 106 (21.0) 73 (24.5) 72 (23.3) 37 (17.2) 34 (17.4)
Intermediate (2 risk factors) 187 (36.5) 183 (36.2) 116 (38.9) 120 (38.8) 71 (33.0) 63 (32.3)
High (3-5 risk factors) 216 (42.1) 215 (42.6) 109 (36.6) 117 (37.9) 107 (49.8) 98 (50.3)b
Induction regimen
Rituximab plus CHOP 386 (75.2) 382 (75.6) 230 (77.2) 248 (80.3) 156 (72.6) 134 (68.4)
Rituximab plus CVP 113 (22.0) 109 (21.6) 56 (18.8) 50 (16.2) 57 (26.5) 59 (30.1)
Rituximab plus FCM 14 (2.7) 14 (2.8) 12 (4.0) 11 (3.6) 2 (0.9) 3 (1.5)
Data are No. (%) unless otherwise specified.
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; ECOG PS,
Eastern Cooperative Oncology Group performance status; FCM, fludarabine, cyclophosphamide, andmitoxantrone; FLIPI, Follicular Lymphoma International
Prognostic Index; MITT, maintenance intent-to-treat; ULN, upper limit of normal.
aData missing in five patients.
bData missing in one patient.
cData missing in two patients.
dData missing in 38 patients.
eData missing in 37 patients.
fData missing in 24 patients.
gData missing in 18 patients.
hData missing in 14 patients.
iData missing in 19 patients.
jFLIPI scores were collected at registration (risk score includes five factors: age [. 60 years], Ann Arbor stage [III or IV], hemoglobin [, 120 g/L], serum
lactate dehydrogenase [. ULN], and number of nodal areas involved [five or more]).
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(47.6%) of 513 in the observation arm had either started
a new chemotherapy treatment or had died before
receiving it.
The above-mentioned beneficial effects of rituximab
maintenance did not translate into an OS benefit (Table 2;
Fig 2D), with 10-year OS rate estimates of approximately
80% (observation, 79.9%; rituximab maintenance, 80.1%)
in both study arms; median OS was not reached in either
arm (HR, 1.04; 95% CI, 0.77 to 1.40; P = .7948). OS
according to FLIPI risk factor categories in patients ran-
domly assigned to rituximab maintenance or observation
is shown in the Data Supplement. OS after progression
or relapse (ie, time from first progression until death)
was shorter in the maintenance arm versus the observa-
tion arm, explaining equivalent OS in both arms (Data
Supplement).
A total of 503 patients had documented disease progres-
sion. The rate of progression with disease transformation
was low, but similar in both study arms (Data Supplement).
No difference in time to transformation was observed (Data
Supplement).
Second-Line Treatment
Of 503 patients who experienced disease progression,
453 received documented second-line (2L) therapy.
The most common subsequent chemotherapy regimens
were rituximab with a platinum-based regimen (27.2%),
fludarabine-based regimen (12.1%), or bendamustine
(8.6%; Data Supplement). Significantly more patients in
the observation arm than in the rituximab maintenance
arm received a rituximab-containing therapy at relapse
or progression (81.5% v 73.2%, respectively; P = .04).
Slightly more patients in the observation arm received
radioimmunotherapy (24.4% v 16.9%, respectively; P =
.06). One hundred twenty patients (26.5%) underwent
high-dose therapy followed by autologous stem-cell
transplantation with no difference between the two arms
(29.3% v 22.4%, respectively; P = .13). Response to 2L
regimen was similar between 1L treatment arms, with
overall response and CR rates of 78.2% and 47.3%, re-
spectively (rituximab maintenance) versus 80.4% and
46.4%, respectively (observation). However, the rate of
CR/CRu for patients who experienced early progression
within 18 months of random assignment (corresponding
to 24 months after induction) was inferior in the main-
tenance arm compared with the observation arm (39.3%
v 56.3%; P = 0.029), thus demonstrating that the patients
who experienced disease progression during mainte-
nance were those with a more aggressive disease (Data
Supplement).
Safety
Since random assignment, 285 patients (56.9%) of 501
in the rituximab maintenance arm and 194 patients
(38.2%) of 508 in the observation arm have experienced
at least one AE (Data Supplement). Rituximab mainte-
nance was associated with a higher rate of grade 3 to
4 AEs (24.4% v 16.9%) and serious AEs (21.2% v
13.4%) compared with observation; the higher rate of
grade 3 to 4 AEs was driven largely by higher rates of
cytopenias (5.2% v 1.6%) and infections (4.4% v 1.0%).
The most common grade 3 to 4 AEs were neoplasms
benign, malignant, and unspecified (including cysts
and polyps), with a similar incidence between study
arms (approximately 4% in both arms). Grade 5 (fatal)
TABLE 2. Overview of Key Efficacy Results After 6 and 9 Years of Follow-Up From Random Assignment
Efficacy Result, years










Median 4.1 NR 4.1 10.5
HR (95% CI), P 0.58 (0.48 to 0.69), , .001 0.61 (0.52 to 0.73), , .001
TTNLT
Median 5.9 NR 6.1 NR
HR (95% CI), P 0.63 (0.52 to 0.76), , .001 0.66 (0.55 to 0.78), , .001
TTNCT
Median 7.1 NR 9.3 NR
HR (95% CI), P 0.70 (0.57 to 0.86), , .001 0.71 (0.59 to 0.86), , .001
OS
Median NR NR NR NR
HR (95% CI), P 1.02 (0.71 to 1.47), .8959 1.04 (0.77 to 1.40), P = .7948
Abbreviations: HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival; TTNCT, time to next chemotherapy
treatment; TTNLT, time to next antilymphoma treatment.
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AEs occurred in eight patients (1.6%) of 501 and
three patients (0.6%) of 508 randomly assigned to rit-
uximab maintenance and observation, respectively
(Data Supplement).
A total of 88 patients (17.4%) have died in the rituximab
maintenance arm since random assignment versus 84
(16.4%) in the observation arm (Table 3). The most fre-
quent causes of death were progressive disease (rituximab
0
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HR, 1.04; 95% CI, 0.77 to 1.40; P = .7948 
FIG 2. Kaplan-Meier estimates of (A) progression-free survival (PFS), (B) time to next antilymphoma treatment (TTNLT), (C) time to next
chemotherapy treatment (TTNCT), and (D) overall survival (OS) from random assignment. HR, hazard ratio.
2820 © 2019 by American Society of Clinical Oncology Volume 37, Issue 31
Bachy et al
Downloaded from ascopubs.org by HYKS/Syopatautien Klinikka on January 29, 2020 from 128.214.144.149
Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
maintenance, 51.1%; observation, 47.6%) and solid tu-
mors (rituximab maintenance, 5.7%; observation, 20.2%).
DISCUSSION
The primary analysis from PRIMA demonstrated prolonged
PFS with rituximab maintenance when applied after 1L
immunochemotherapy induction to patients with previously
untreated, high–tumor-burden FL.17 This long-term follow-up
strengthens these previously published results,17,18 demon-
strating significantly longer PFS, TTNLT, and TTNCT in the
rituximab maintenance arm compared with the observation
arm. With an updated 9-year median follow-up, projected
10-year PFS was 51.1% in the rituximab maintenance arm
and 35.0% in the observation arm, whereas 10-year TTNLT
estimates were 53.4% and 41.2%, respectively. Clinically,
these results mean that approximately half of patients who
receive rituximab maintenance every 8 weeks for 2 years after
response to immunochemotherapy induction will remain free
from progression or death and free from further anti-
lymphoma treatment after 10 years. Subgroup analyses
showed the substantial PFS improvement associated with
rituximab maintenance was independent of age, sex, in-
duction immunochemotherapy regimen, response to in-
duction (CR/CRu, or PR), or FLIPI risk score.
The OS estimate at 10 years for the whole patient cohort
was approximately 80%, thus confirming how the intro-
duction of rituximab into the therapeutic armamentarium in
general, and into the 1L induction setting in particular, has
profoundly altered the course of FL, as compared with
historical controls.21,22 However, despite significant and
sustained PFS prolongation with rituximab maintenance,
no OS difference was observed between the two arms. This
finding is similar to recently published long-term follow-up
studies in which prolonged PFS with the use of rituximab
plus CHOP (compared with rituximab plus CVP) or rituximab
plus bendamustine (compared with rituximab plus CHOP)
fails to translate into prolonged OS23,24 and has important
implications for both our understanding of the disease and
future research in the field. First, direct extrapolation of PFS
as a surrogatemarker for OS cannot bemade in FL, even with
long-term follow-up. Second, PFS and TTNLT prolongation as
meaningful clinical and economic end points must be viewed
independently of OS. And third, the underlying biologic ex-
planation for PFS improvement not translating into longer OS
needs to be addressed.
Recent efforts have been made by the Follicular Lymphoma
Analysis of Surrogacy Hypothesis) group to assess if CR at
30 months after initiation of induction therapy can serve as
a surrogate end point for PFS in FL, and the initial results look
promising.25 However, the evidence for PFS as a surrogate for
OS is conflicting. In advanced solid tumors, there is con-
siderable heterogeneity among cancer types and, for a given
neoplasm, there are even discrepancies among the same
histology subgroups, resulting in a generally low strength of
association between PFS and OS.26 In lymphoma, surrogacy
has been studied and documented in 1L diffuse large B-cell
lymphoma,27 but robust data are lacking in FL. Indeed,
statistical modeling indicates that the association between
PFS and OS tends to be weaker for malignancies with a long
survival after progression, such as FL, which explains how the
PFS advantage reported here may have been diluted over
subsequent lines of treatment.28 Whether the recently






Total deaths, No. 84 88
Lymphoma progression 40 (47.6) 45 (51.1)
Solid tumor* 17 (20.2) 5 (5.7)
Infection† 5 (6.0) 11 (12.5)
AML/MDS 7 (8.3) 4 (4.6)
Cardiovascular event 5 (6.0) 9 (10.2)
Direct toxicity during subsequent treatment‡ 1 (1.2) 3 (3.4)
Other cause 3 (3.6) 6 (6.8)
Unevaluable event 6 (7.1) 5 (5.7)
Data presented as No. (%) unless otherwise noted.
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.
*Solid tumors in the observation arm: lung cancer (n = 3), melanoma (n = 2), neuroendocrine carcinoma of the skin (n = 1), ovarian cancer
(n = 2), malignant astrocytoma (n = 1), glioblastoma (n = 1), hepatocellular carcinoma (n = 1), metastatic neoplasm of unknown origin (n = 1),
prostate cancer (n = 1), rectal adenocarcinoma (n = 1), salivary gland cancer (n = 1), tongue neoplasm (n = 1), cancer without precision (n = 1);
solid tumors in the maintenance arm: lung cancer (n = 2), neuroendocrine carcinoma of the skin (n = 1), hepatocellular carcinoma (n = 1), and
anal carcinoma (n = 1).
†Progressive multifocal leukoencephalopathy: one in each arm.
‡Toxicity during allogeneic stem-cell transplantation (n = 3) and idelalisib treatment (n = 1).
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described progression of disease within 24 months of
initiating treatment end point is a more reliable surrogate of
OS in patients with FL receiving 1L immunochemotherapy
with or without maintenance remains to be established.29-32
In our analysis, the proportion of deaths associated with
lymphoma progression was almost identical between
treatment arms. Response to 2L treatment was also com-
parable. Shorter survival after first relapse in the mainte-
nance arm helps to explain why OS was similar in both
arms despite prolonged PFS. Altogether, these data in-
dicate that rituximab maintenance does not alter the nat-
ural course of the disease for patients with aggressive FL
and that they will ultimately die as rapidly as if they were
observed after induction treatment. Whether the absence of
an OS benefit in these patients challenges the appeal of a
prolonged 1L remission in most patients with de novo FL
with a high tumor burden remains an open question.
No difference in terms of transformation rate was found with
this extended follow-up, and these findings confirmed a
previous analysis of data from the PRIMA cohort, which
showed that rituximab maintenance did not have a signif-
icant prognostic impact on histologic transformation.33
Interestingly, detailed analysis of 2L treatments at re-
lapse showed that use of rituximab was significantly less
frequent after rituximab maintenance than after observa-
tion. Data on the use of anti-CD20 antibodies as mainte-
nance at relapse were lacking, but one could hypothesize
that rituximab maintenance may have been more frequently
administered in the observation arm, given the established
beneficial effect of rituximab maintenance on PFS in the
relapsed/resistant setting.34 This could potentially explain,
at least in part, the absence of a difference in OS between
the two arms.
Consistent with previous analyses,17,18 rituximab mainte-
nance was generally well tolerated, and no unexpected
safety signals were observed with the additional 4 years of
follow-up. It is worth noting that although the OS rate was
not different between the two arms, death due to second
neoplasia was almost four times more frequent in the ob-
servation arm compared with the maintenance arm. It could
be speculated that recurrent use of cytotoxic- and radiation-
containing regimens in the context of earlier relapse in the
observation arm may have increased the frequency of second
neoplasms. Conversely, deaths due to infection, a known
consequence of immunotherapy,34 were twice as frequent
in the rituximabmaintenance arm. However, only two cases
of the opportunistic infection, progressive multifocal leu-
koencephalopathy, were observed, one in each treatment
arm. Although rituximab exposure may increase this risk,35
our data suggest there is not a strong effect of maintenance.
In conclusion, this 9-year follow-up of the PRIMA study
demonstrates that rituximab maintenance after induction
immunochemotherapy provides a significant long-term
PFS benefit over observation. Despite the lack of OS ad-
vantage, it is noteworthy that more than half of the patients
in the rituximab maintenance arm remain free of disease
progression and have not required new antilymphoma
treatment beyond 10 years.
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19Institut Curie–Hôpital Rene Huguenin, Saint-Cloud, France
20Institut Universitaire du Cancer de Toulouse–Oncopole, Toulouse,
France
21Saint Antoine Hospital, Assistance Publique–Hôpitaux de Paris, Paris,
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Cancérologie et Immunologie Nantes Angers, INSERM, Université de
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